IPASS
Regimen
- Experimental
- gefitinib
- Control
- carboplatin+paclitaxel
Population
East Asian never/light-smoker adenocarcinoma, clinically selected
Key finding
In EGFR-mut subset PFS HR 0.48 (0.36-0.64); in EGFR-WT HR 2.85 (2.05-3.98); proved EGFR status is predictive
Source: PMID 19692680
Timeline
- Enrollment start: 2006-03 📎
Guideline citations
- CSCO NSCLC 2025 ⚠️ OCR source